Follow-up Study of Autologous Cultured Adipose-derived Stem Cells for the Crohn's Fistula (ANTG-ASC-203)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
The patients who have participated in phase II clinical trial (ANTG-ASC-202) and injected with Adipoplus at least once.
the patients who have participated in ANTG-ASC-202 clinical trial
the patients who have experienced with Adipoplus in ANTG-ASC-202 trials
the patients who submit written consents and is able to obey requirements of trials
pregnant or breast feeding
autoimmune disease other than Crohn's disease
infectious diseases including HBV, HCV or HIV
who is not willing to use effective contraceptive methods during the study.
moderate to severe active or worsened Crohn's disease
who have received Infliximab during or after ANTG-ASC-202 trial